HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment.

Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a member of the growing family of neurotrophic and neuroprotective factors playing important roles during neuronal development and protection against different types of injuries, such as Parkinson's disease, excitotoxicity, and ischemia. As shown with other neuronal tissues, we provide evidence that PACAP is protective in the retina against toxic injury induced by monosodium glutamate (MSG) in vivo. The need for characterization of its fragments and analogues has recently been emphasized. The aim of the present study was to compare the effects of the physiologically occurring fragments PACAP1-38 and 1-27 and the widely used antagonists (PACAP6-38 and 6-27) in retinal degeneration induced by MSG in neonatal pups. Histological analysis showed that MSG treatment caused the degeneration of the entire inner plexiform layer and the inner nuclear and ganglion cell layers seemed fused. The total thickness of the retina was significantly reduced. Similar and substantial protective effects could be observed after three treatments with PACAP1-38 and 1-27, while MSG toxicity was further aggravated by the PACAP antagonists PACAP6-38 and 6-27. Glutamate-induced toxicity is known to play a role in several retinal pathologies. Our results provide further evidence for the effectiveness of the endogenously present PACAP forms in counteracting retinotoxicity and call for further studies leading to the discovery of potent analogues that could be used in human ophthalmic diseases.
AuthorsTamás Atlasz, Krisztina Szabadfi, Dóra Reglodi, Péter Kiss, Andrea Tamás, Gábor Tóth, Alexandra Molnár, Klaudia Szabó, Róbert Gábriel
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1163 Pg. 348-52 (Apr 2009) ISSN: 1749-6632 [Electronic] United States
PMID19456357 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Peptide Fragments
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Sodium Glutamate
Topics
  • Animals
  • Animals, Newborn
  • Peptide Fragments (therapeutic use)
  • Pituitary Adenylate Cyclase-Activating Polypeptide (therapeutic use)
  • Rats
  • Rats, Wistar
  • Retinal Degeneration (chemically induced, drug therapy)
  • Sodium Glutamate (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: